Five months after KalVista was staggered by an FDA clinical hold on its Phase II trial for KVD824, their oral drug to treat attacks caused by hereditary angioedema (HAE), the biotech is reporting progress outside the US.
Elixiron closes $27 million series A to test lead asset, an oral CSF1R inhibitor, in Alzheimer's patients and launch a trial in vitiligo patients.